Salute e Benessere

Santen Receives UK Approval for Ryjunea® (low-dose atropine 0.1 mg/ml) to Slow…

The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance.[6] Myopia can affect learning, confidence, and participation in school and play.[9] Early interventions are key to slowing progression and supporting children's eye health and wellbeing.[10] The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise...
PR Newswire
05/11/2025

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a…

A cardiometabolic post hoc analysis from the OASIS 4 phase 3 clinical trial examined how the amount of weight patients lost affects glycemic parameters (blood sugar control) and cardiovascular (CV) risk factors in adults with overweight and obesity. In participants with overweight or obesity, once-daily oral semaglutide 25 mg treatment compared with placebo led to greater improvements in glycemic parameters, including HbA1c, fasting plasma glucose, and fasting serum insulin, as well as CV risk…
PR Newswire
05/11/2025

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten…

ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at an offering price per share of $10.50. The gross proceeds from the offering to MoonLake, before deducting the underwriting discounts and commissions and other...
Nasdaq GlobeNewswire
05/11/2025

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and…

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefitReported an interim analysis of the long-term data from the VELA-1...
Nasdaq GlobeNewswire
05/11/2025

NCH Becomes First U.S. Hospital to Use AI That Detects Hidden Heart Attack Risk…

Caristo's FDA-cleared CaRi-Plaque™ technology analyzes coronary CT angiography (CCTA) scans, the first-line test for patients with chest pain, to identify high-risk plaque that may lead to future heart attacks. CaRi-Heart™ is the only technology in the world able to detect and quantify coronary inflammation, an early driver of heart disease, without waiting for patients to develop visible plaque. Caristo's FDA-clearedCaRi-Plaque™technology analyzes coronary CT angiography (CCTA) scans, the...
PR Newswire
05/11/2025

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of…

ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiated profile; Expect to initiate patient studies in Q1 2026 ...
Nasdaq GlobeNewswire
05/11/2025

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3…

For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United States segment increased by 12%; Europe segment decreased by 10% in LC; and International Markets segment decreased by 10% in LC, or increased by 2% in LC excluding Japan BV...
Nasdaq GlobeNewswire
05/11/2025

Private Placement of Financière de Tubize shares

Financière de Tubize has been informed that a block of 882k existing ordinary shares (1,98% of Financière de Tubize capital) has been offered yesterday, after Euronext Brussels market close, within the framework of a private placement (Accelerated Bookbuild). This is the result of the donation of a non-family shareholder to some not-for-profit organisations who mandated Bank Degroof Petercam to sell their shares.
Nasdaq GlobeNewswire
05/11/2025

AMP 2025: DNAe to unveil latest data from world's first NGS-based, fully…

Samuel Reed, CEO of DNAe, commented: "We're heading to AMP at a hugely exciting phase in the delivery of our LiDia-SEQ™ diagnostic platform, with news of our latest datasets already generating strong interest across the molecular diagnostics community. Our focus now is on completing the development of our flagship BSI/AMR test on the LiDia-SEQ™ platform – a highly sensitive, fully automated test from whole blood samples that will enable rapid detection and identification of life-threatening…
PR Newswire
05/11/2025

Companion Diagnostics Market Worth USD 15.6 Bn by 2030 Growing at 12.4% CAGR…

North America continues to dominate the companion diagnostics market, supported by a robust pharmaceutical pipeline, favorable reimbursement policies, and early adoption of molecular testing technologies. The region's regulatory clarity from the FDA for co-development of drugs and diagnostics has also streamlined commercialization pathways. North America continues to dominate the companion diagnostics market, supported by a robust pharmaceutical pipeline, favorable reimbursement policies,...
PR Newswire
05/11/2025

Novogene Expands UK Offerings with Launch of ONT-Based Whole Plasmid Sequencing…

Novogene's Whole Plasmid Sequencing service provides full coverage for plasmids up to tens of kilobases in length, ensuring complete and accurate characterisation. With a streamlined workflow, researchers can benefit from next-day turnaround and high-quality, long-read data. Novogene's Whole Plasmid Sequencing service provides full coverage for plasmids up to tens of kilobases in length, ensuring complete and accurate characterisation. With a streamlined workflow, researchers can benefit from...
PR Newswire
05/11/2025

Oculis to Participate in Upcoming November Investor Conferences

/ XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis’ management will participate in upcoming investor conferences in November.Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology...
Nasdaq GlobeNewswire
05/11/2025

Natural Field will Launch "Ashwagandha White Paper" at FTA Forum in Hangzhou

The Ashwagandha White Paper compiles years of research, including analytical data, quality evaluation protocols, and practical applications in functional formulations. By providing clear scientific insights and standardized references, it serves as a critical resource for R&D teams, product developers, and brand innovators worldwide seeking premium botanical ingredients. TheAshwagandha White Papercompiles years of research, including analytical data, quality evaluation protocols, and...
PR Newswire
05/11/2025

Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for…

"We are very pleased to enter this partnership with Karo Healthcare, which has a strong commercial presence across Europe. Launching MOB-015/Terclara® under the well-known Lamisil® brand gives us an exceptional opportunity to establish the product as the market leader also beyond Sweden and Norway," says Anna Ljung, CEO of Moberg Pharma. "We are very pleased to enter this partnership with Karo Healthcare, which has a strong commercial presence acrossEurope. Launching…
PR Newswire
05/11/2025

Top-rated Canadian healthcare provider adopts Sectra's enterprise imaging as a…

"As Sectra will take full responsibility for the system's technology, it will ease the burden on our IT team. We also hope to enhance diagnostic speed for our physicians as this transition will provide them with tools for increased efficiency and improved collaboration capabilities. We are happy to begin implementing Sectra's cloud solution and are looking forward to experiencing the benefits it will bring for our organization and staff," says Amir Soheili, Vice President, Digital…
PR Newswire
05/11/2025

Karo Healthcare enters an exclusive license agreement with Moberg Pharma for…

The agreement further strengthens our position in the foot health category, one of Karo's core focus areas, where we already have established brands and deep expertise across commercial execution, consumer insights, and regulatory know-how. The agreement further strengthens our position in the foot health category, one of Karo's core focus areas, where we already have established brands and deep expertise across commercial execution, consumer insights, and regulatory know-how. MOB-015,...
PR Newswire
05/11/2025

ACTO UNVEILS ACTOVERSE: A PARTNER SOLUTIONS MARKETPLACE DRIVING INNOVATION AND…

ACTOverse simplifies how biopharmaceutical and medical device companies discover, evaluate, and deploy complementary content, data, and services that enhance field training and enablement. ACTOverse partner solutions are pre-vetted by ACTO and built to work seamlessly with the ACTO platform for turnkey implementation and faster time-to-value. ACTOverse simplifies how biopharmaceutical and medical device companies discover, evaluate, and deploy complementary content, data, and services that...
PR Newswire
05/11/2025

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

COPENHAGEN, Denmark, November 5, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.92% of the shares and voting rights in Bavarian Nordic A/S as of October 30, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...
Nasdaq GlobeNewswire
05/11/2025

TME Pharma advances its new investment strategy and signs LOI with German…

TME Pharma advances its new investment strategy and signs LOI with German resources companyA further step toward investment diversification into potential cash-flow–generating assets A potential strategic investment in sustainable tailings reprocessing and environmental rehabilitation projects for precious metals with strong value-creation prospects. Upon successful completion of due diligence, the proposed transaction will be submitted to shareholders at an Extraordinary...
Nasdaq GlobeNewswire
05/11/2025

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the…

Bagsværd, 5 November, 2025 - Financial report for the period 1 January 2025 to 30 September 2025 Operating profit increased by 5% in Danish kroner and 10% at constant exchange rates (CER) to DKK 95.9 billion, impacted by one-off restructuring costs of around DKK 9 billion related to the company-wide transformation with the aim of streamlining Novo Nordisk's operations to...
Nasdaq GlobeNewswire
05/11/2025

Santhera Closes USD 13 Million Royalty Monetization Agreement

Pratteln, Switzerland, November 5, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support the global launches of AGAMREE® (vamorolone). The agreement was initially secured in September 2025 with R-Bridge, an affiliate of CBC Group, covering 25% of net royalties on AGAMREE from Catalyst Pharmaceuticals, Inc. in North America and Sperogenix Therapeutics Ltd in China. Since initially...
Nasdaq GlobeNewswire
05/11/2025

Tinnitus UK Rates Lenire as Most Effective Treatment Option

"Neuromod welcomes Tinnitus UK's decision to recognise Lenire, and bimodal neuromodulation, as a safe and effective standard of care for tinnitus treatment," said Neuromod founding CEO, Dr. Ross O'Neill. "Millions of people in the UK and across Europe rely on Tinnitus UK for advice about treatment options and we are delighted that Neurmod's commitment to building compelling evidence is reflected in this new rating for Lenire." "Neuromod welcomes Tinnitus UK's decision to…
PR Newswire
05/11/2025

Mölnlycke® establishes first wound care manufacturing site in China

The manufacturing site, spanning 10,000 m2, will be set up in accordance with Mölnlycke's global standards and is expected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027. This strategic move will help future-proof Mölnlycke's growth in China, laying the foundation for future capacity expansion and local job creation. The manufacturing site, spanning10,000 m2, will be set up in accordance with Mölnlycke's global standards and is expected to initiate...
PR Newswire
05/11/2025

Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR…

Cholestatic Pruritus Market Summary Cholestatic Pruritus Market Summary Discover the cholestatic pruritus new treatment @New Treatments for Cholestatic Pruritus Key Factors Driving the Growth of the Cholestatic Pruritus Market PBC as the Leading Contributor to Disease Burden Cholestatic pruritus posed a significant clinical burden across rare liver diseases in the US in 2024, with approximately 76K cases in PBC, followed by PSC, ALGS, biliary atresia, and PFIC...
PR Newswire
04/11/2025
Altri  Comunicati